Novel Prognostic and Therapeutic Biomarker for Cancer and Inflammatory Diseases
Posted Oct 24 2010 8:00pm
Description of Invention: There remains a significant unmet need for diagnostics, prognostics, and therapeutics for conditions that involve inflammation and the formation of blood clots such as bleeding disorders, trauma, and diseases such as sepsis, cardiovascular disease, stroke, and cancer. The global market for such products is varied and competitive, and is forecast to be over $40 billion by 2010.
Researchers at the National Cancer Institute (NCI) have identified that levels of a novel soluble protein involved in the repair mechanism for damaged blood vessels correlate with outcome in sepsis and with the diagnosis of disseminated intravascular coagulation, a contributing factor to the morbidity and mortality associated with sepsis.
Further, the NCI researchers have demonstrated that a recombinant version of this novel protein facilitates the clotting of blood, suggesting a potentially significant therapeutic benefit for the treatment of bleeding disorders or trauma.
Diagnostic and prognostic biomarker for diseases that involve inflammation and blood clot formation (i.e., sepsis, cardiovascular disease, stroke, cancer)
Treatment of bleeding disorders or trauma
Treatment of cerebral bleeding associated with aneurism or stroke
Therapy for patients with low platelet counts
Therapy for women suffering from preeclampsia or thrombotic episodes
Protein levels correlate with disease state/outcome
Administration of recombinant protein accelerates the formation of blood clots
Washington AV et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest. 2009 Jun;119(6):1489-1501. [ PubMed: 19436112 ]
Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009 Feb;21(1):38-46. [ PubMed: 19230638 ]
Licensing Status: Available for licensing
Collaborative Research Opportunity: The Center for Cancer Research, Cancer and Inflammation Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize soluble TREM receptor proteins. Please contact John Hewes, Ph.D. at 301-435-3121 or email@example.com for more information. Click here to view the NCI collaborative opportunity announcement.
Portfolios: Cancer Cancer - Diagnostics Internal Medicine Internal Medicine - Diagnostics Internal Medicine - Therapeutics
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220